Clinical trials
Phase 3 Squamous Cell Carcinoma of Head and Neck trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 2 |
| 2010 | 1 |
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 16 |
| Completed | 4 |
| Not yet recruiting | 3 |
| Terminated | 2 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Merck KGaA, Darmstadt, Germany | 2 |
| Merck Sharp & Dohme LLC | 2 |
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | 2 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2 |
| Sun Yat-sen University | 2 |
| Akeso | 1 |
| Beijing Tongren Hospital | 1 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1 |
| EMD Serono Research & Development Institute, Inc. | 1 |
| Fudan University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Squamous Cell Carcinoma of Head and Neck | 28 |
| Head and Neck Neoplasms | 5 |
| Carcinoma, Squamous Cell | 1 |
| Hypopharyngeal Neoplasms | 1 |
| Laryngeal Neoplasms | 1 |
| Mouth Neoplasms | 1 |
| Tongue Neoplasms | 1 |
Trials
Showing 1 to 25 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.